Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 115, Issue 6, Pages 691-702
Publisher
Springer Nature
Online
2016-08-17
DOI
10.1038/bjc.2016.236
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma
- (2015) Hideharu Bessho et al. CANCER INVESTIGATION
- Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
- (2015) Anwar R. Padhani et al. NEOPLASIA
- Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology
- (2015) Mary E. Loveless et al. NEOPLASIA
- Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
- (2014) J. P. B. O'Connor et al. CLINICAL CANCER RESEARCH
- Emerging applications for ferumoxytol as a contrast agent in MRI
- (2014) Mustafa R. Bashir et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts
- (2013) Siver A. Moestue et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors
- (2013) Markus Thomas et al. PLoS One
- Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?
- (2012) N Tunariu et al. BRITISH JOURNAL OF CANCER
- The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
- (2012) L C J Baker et al. BRITISH JOURNAL OF CANCER
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
- (2012) R. S. Turley et al. CLINICAL CANCER RESEARCH
- Qualification of imaging biomarkers for oncology drug development
- (2012) John C. Waterton et al. EUROPEAN JOURNAL OF CANCER
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study
- (2012) I.M.E Desar et al. CANCER IMAGING
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas
- (2011) Jessica KR Boult et al. JOURNAL OF PATHOLOGY
- Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging
- (2011) Jake S. Burrell et al. MAGNETIC RESONANCE IN MEDICINE
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
- (2010) H. Hashizume et al. CANCER RESEARCH
- Bayesian estimation of changes in transverse relaxation rates
- (2010) Simon Walker-Samuel et al. MAGNETIC RESONANCE IN MEDICINE
- A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
- (2010) J. L. Brown et al. MOLECULAR CANCER THERAPEUTICS
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
- (2010) Carol Kilkenny et al. PLOS BIOLOGY
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
- (2009) J. P.B. O'Connor et al. CLINICAL CANCER RESEARCH
- Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors
- (2009) Simon Walker-Samuel et al. MAGNETIC RESONANCE IN MEDICINE
- Angiopoietin-2: Development of inhibitors for cancer therapy
- (2009) Bo Hu et al. Current Oncology Reports
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives
- (2008) James PB O'Connor et al. LANCET ONCOLOGY
- Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate
- (2008) Daniel P. Bradley et al. MAGNETIC RESONANCE IMAGING
- Mapping and quantifying mammalian transcriptomes by RNA-Seq
- (2008) Ali Mortazavi et al. NATURE METHODS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started